Join
Live feed
·
PRReleasevia Quantisnow
Alzamend Neuro Inc. logo

Alzamend Neuro Reports Positive Topline Data from Phase II Clinical Trial of AL001 "Lithium in Brain" Study; AL001 Achieves Bioequivalence and Demonstrates Superior Brain Delivery Across All Measured Brain Regions

ByQuantisnow·Wall Street's wire, on your screen.
ALZN· Alzamend Neuro Inc.
Health Care

This insight was delivered by - Wall Street's wire, on your screen. Quantisnow is a real-time market data and news platform for retail investors, aggregating SEC filings, FDA approvals, analyst ratings, insider trading, and press releases into a single customizable feed. Track ALZN (Alzamend Neuro Inc.) and more on Quantisnow.